JP2013539857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539857A5 JP2013539857A5 JP2013528723A JP2013528723A JP2013539857A5 JP 2013539857 A5 JP2013539857 A5 JP 2013539857A5 JP 2013528723 A JP2013528723 A JP 2013528723A JP 2013528723 A JP2013528723 A JP 2013528723A JP 2013539857 A5 JP2013539857 A5 JP 2013539857A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- treatment
- mdsc
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 28
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 229940022399 cancer vaccine Drugs 0.000 claims 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 4
- 102100022338 Integrin alpha-M Human genes 0.000 claims 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 238000009007 Diagnostic Kit Methods 0.000 claims 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 3
- 102100025390 Integrin beta-2 Human genes 0.000 claims 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000013610 patient sample Substances 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 102100035793 CD83 antigen Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- -1 IL4Ra Proteins 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 210000005008 immunosuppressive cell Anatomy 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101150008417 LIN gene Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478410P | 2010-09-21 | 2010-09-21 | |
| GB1015765.9 | 2010-09-21 | ||
| US61/384,784 | 2010-09-21 | ||
| GBGB1015765.9A GB201015765D0 (en) | 2010-09-21 | 2010-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
| PCT/EP2011/066397 WO2012038463A2 (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013539857A JP2013539857A (ja) | 2013-10-28 |
| JP2013539857A5 true JP2013539857A5 (OSRAM) | 2014-10-30 |
| JP5970459B2 JP5970459B2 (ja) | 2016-08-17 |
Family
ID=43065538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013528723A Expired - Fee Related JP5970459B2 (ja) | 2010-09-21 | 2011-09-21 | がん診断用バイオマーカーに対する骨髄細胞の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9671404B2 (OSRAM) |
| EP (1) | EP2619585B1 (OSRAM) |
| JP (1) | JP5970459B2 (OSRAM) |
| KR (1) | KR20130137635A (OSRAM) |
| CN (1) | CN103180739B (OSRAM) |
| CA (1) | CA2811070A1 (OSRAM) |
| EA (1) | EA201390413A1 (OSRAM) |
| GB (1) | GB201015765D0 (OSRAM) |
| SG (2) | SG10201510470WA (OSRAM) |
| WO (1) | WO2012038463A2 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP3682896A1 (en) * | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013169913A1 (en) | 2012-05-08 | 2013-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Predictors of patient response to interferon-a therapy |
| EP2968557A4 (en) * | 2013-03-13 | 2016-09-28 | Health Research Inc | IMPROVING VACCINES |
| CN103743907B (zh) * | 2013-07-24 | 2015-04-15 | 北京大学人民医院 | 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法 |
| WO2015048748A1 (en) * | 2013-09-30 | 2015-04-02 | Board Of Regents, The University Of Texas System | Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use |
| CN103626846B (zh) * | 2013-11-08 | 2016-06-01 | 上海交通大学 | 与MDSCs特异性结合的配体多肽及药物输送系统 |
| EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| CA2990852A1 (en) * | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| WO2017041043A1 (en) * | 2015-09-02 | 2017-03-09 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| HRP20241316T1 (hr) | 2016-04-14 | 2024-12-20 | Ose Immunotherapeutics | Nova anti-sirpa antitijela i njihove terapijske primjene |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| CN107102127B (zh) * | 2017-04-07 | 2019-08-06 | 东北师范大学 | 一种人体外周血中单核样髓源抑制细胞的检测方法 |
| EP3624848A1 (en) | 2017-05-19 | 2020-03-25 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| CN110023760B (zh) * | 2017-06-02 | 2023-04-14 | 李宗均 | 一种利用结直肠癌患者和正常人外周血内免疫细胞的分布差异评估免疫力并提供结直肠癌发病情况信息的诊断工具 |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
| KR20260008173A (ko) | 2017-11-22 | 2026-01-15 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| KR102216725B1 (ko) * | 2017-12-29 | 2021-02-17 | 연세대학교 산학협력단 | 면역 항암 요법에 대한 치료 반응 예측 방법 |
| WO2019175218A1 (en) | 2018-03-13 | 2019-09-19 | Ose Immunotherapeutics | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
| AU2019266231B2 (en) | 2018-05-07 | 2025-08-21 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| CN110501483B (zh) * | 2019-07-25 | 2020-12-29 | 同济大学 | 一种中草药活性的检测方法 |
| TR202003833A1 (tr) | 2020-03-12 | 2021-09-21 | Hacettepe Ueniversitesi Rektoerluek | Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇ |
| CA3218692A1 (en) | 2021-06-04 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
| CN117030580B (zh) * | 2023-09-15 | 2024-07-16 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | LDNs在坏死性小肠结肠炎诊断中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US20040136973A1 (en) * | 2002-11-07 | 2004-07-15 | Eliezer Huberman | Human stem cell materials and methods |
| US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| GB0820698D0 (en) * | 2008-11-12 | 2008-12-17 | Ludwig Inst Cancer Res | Uses of immunomodulators |
-
2010
- 2010-09-21 GB GBGB1015765.9A patent/GB201015765D0/en not_active Ceased
-
2011
- 2011-09-21 EA EA201390413A patent/EA201390413A1/ru unknown
- 2011-09-21 US US13/239,011 patent/US9671404B2/en not_active Expired - Fee Related
- 2011-09-21 SG SG10201510470WA patent/SG10201510470WA/en unknown
- 2011-09-21 CA CA2811070A patent/CA2811070A1/en not_active Abandoned
- 2011-09-21 JP JP2013528723A patent/JP5970459B2/ja not_active Expired - Fee Related
- 2011-09-21 EP EP11758209.8A patent/EP2619585B1/en active Active
- 2011-09-21 SG SG2013018973A patent/SG188543A1/en unknown
- 2011-09-21 WO PCT/EP2011/066397 patent/WO2012038463A2/en not_active Ceased
- 2011-09-21 KR KR1020137010009A patent/KR20130137635A/ko not_active Withdrawn
- 2011-09-21 CN CN201180045200.3A patent/CN103180739B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Dual TGF‐β and PD‐1 blockade synergistically enhances MAGE‐A3‐specific CD8+ T cell response in esophageal squamous cell carcinoma | |
| Lou et al. | miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer | |
| Chow et al. | Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy | |
| Tumino et al. | Polymorphonuclear myeloid-derived suppressor cells are abundant in peripheral blood of cancer patients and suppress natural killer cell anti-tumor activity | |
| Solito et al. | Myeloid‐derived suppressor cell heterogeneity in human cancers | |
| Vujanovic et al. | CD56dim CD16− natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α | |
| De Monte et al. | Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients | |
| Yanagisawa et al. | WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study | |
| Xu et al. | Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma | |
| Kalathil et al. | Higher frequencies of GARP+ CTLA-4+ Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality | |
| Liotta et al. | Frequency of regulatory T cells in peripheral blood and in tumour‐infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma | |
| Kimura et al. | Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines | |
| Avril et al. | Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions | |
| Martin et al. | Mobilization of viable tumor cells into the circulation during radiation therapy | |
| KR20130137635A (ko) | 암의 진단을 위한 골수 세포 생체지표의 용도 | |
| Hughes et al. | Mycosis fungoides and S ézary syndrome: Current challenges in assessment, management and prognostic markers | |
| Kakita et al. | Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25− FOXP3− T cells | |
| Atreya et al. | The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer | |
| Nair et al. | Immunologic targeting of FOXP3 in inflammatory breast cancer cells | |
| JP2018527570A5 (OSRAM) | ||
| Liang et al. | FOXA1+ regulatory T cells: A novel T cell subset that suppresses antitumor immunity in lung cancer | |
| Heidari et al. | Effects of indoleamine 2, 3‐dioxygenase (IDO) silencing on immunomodulatory function and cancer‐promoting characteristic of adipose‐derived mesenchymal stem cells (ASCs) | |
| Ryuge et al. | Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung | |
| Núñez et al. | Tumor‐associated macrophages impair NK cell IFN‐γ production and contribute to tumor progression in clear cell renal cell carcinoma | |
| Beyer et al. | Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3 |